This study investigates metastatic pancreatic cancer. It looks at the effects of an investigational medication combined with chemotherapy, with or without an additional investigational treatment.
The study evaluates the safety and effectiveness of the investigational treatments in improving clinical outcomes compared to standard chemotherapy.
- Who can participate: Adults aged 18 to 75 years with metastatic pancreatic cancer may join. Key factors include having a good performance status and no prior systemic treatment for this cancer.
- Study details: Participants will receive either the investigational medication with or without an additional treatment, or a placebo, all combined with chemotherapy. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.